Back to All

Diaceutics' Pharma Precision Medicine Readiness Report 2019: It's time to rethink the testing-treatment relationship

22 October, 2019

The diagnostic testing ecosystem is broken, hindering the progress of Precision Medicine in 2019, according to Diaceutics’ just published Pharma Precision Medicine Readiness Report 2019. In this latest annual assessment of the state of Precision Medicine, Diaceutics calls on the Precision Medicine community to rethink the relationship between testing and treatment, and end the “siloed thinking that is denying patients access to the right tests and better treatments.”

In the Report, Diaceutics draws on its experience with more than 500 therapy/diagnostic projects and the insights derived from real-world data to depict the toll that this fragmented commercial approach is having on patients. The Report reveals the challenges and strategic mistakes that continue to impair the onward march of Precision Medicine, including those involving the diagnostic supply chain, relations between the Pharma and Lab industries, suboptimal investment in biomarker/therapy combinations, and core hurdles to optimal precision testing facing Pharma commercial teams.

Additionally, the Report

  • Describes Diaceutics’ solution to this broken diagnostic testing ecosystem through the global harmonization of clinical lab tests,
  • Identifies the megatrends characterizing Precision Medicine in 2019, and
  • Predicts the drivers and disruptors that will shape Precision Medicine in the next 3 to 5 years.

Download the full Diaceutics Pharma Precision Medicine Readiness Report 2019  here to get the full story on Precision Medicine!

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny